Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

17    Gilead Sciences    $5.5B    up 17.0%
Global revenue: $8.4B (18th); up 6.3%

R&D spend: $1.2B (17th), up 14.5%; 14.6% of rev.

Top brands: Atripla ($2.6B), Truvada ($2.0B); Viread ($466M), Ranexa ($320M), Hepsera ($69M)

Planned launches: Cobicistat (HIV/AIDS), “Quad” pill (HIV/AIDS), GS-7977 (HCV)

Promotional spend: $32M (18th); 0.6% of rev.

Patent expirations: Hepsera (2014), Letairis (2015), Viread (2017)

This specialty biopharma firm remains highly competitive, most notably in antivirals. The leader in the field, Gilead launched HIV/AIDS drug Complera last year and filed the “Quad pill” for approval (set for FDA review in August). Complera and Quad represent important advances, and analysts expect both to get approved and to snag the bulk of new patient starts in coming years, although Gilead's top seller, HIV/AIDS med Atripla, is not scheduled to lose exclusivity until 2021 and despite a generic version of Combivir. The firm also leaped ahead in the hotly contested race to market an all-oral/interferon-free hepatitis C therapy, buying biotech Pharmasset for $11 billion and access to that firm's Phase III pipeline asset GS-7977. The company also plays in the cardiovascular arena, where angina drug Ranexa is selling well, and the FDA's removal of a warning from the label of PAH product Letairis could mean higher sales of that drug. Despite a manufacturing shortage, the drug Cayston also plays an important role in treating pseudomonas aerugonisa in cystic fibrosis patients.

Back to first page

Page 17 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?